Abstract
Prolactinoma is the most common intracranial neoplasms. Although prolactinoma is always treated with anticarcinogen, many patients recurrence after curing. This indicates that we need to identify a new mechanism for the treatment of prolactinoma. In order to recognize new biomarkers, we identify the differentially expressed genes (DEGs) by the microarray. A total of 86 DEGs are identified including 35 up-regulated genes and 51 down-regulated genes. The set of DEGs can distinguish tumor samples and normal samples significantly. The genes are mainly enriched in 33 Go terms and 2 kegg pathways associated with prolactinoma. In order to recognize the function of DEGs, we import these genes into protein-protein interaction network to analyze these genes. For example, MDM2, LYN, CDH1, GH1, ACTG1 and FUS play an important role in prolactinoma. In summary, the gene set we recognize can provide potential effect for treatment of prolactinoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
